
Annual report 2025
added 03-21-2026
Immutep Limited EPS Ratio 2011-2026 | IMMP
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Immutep Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -5.03 | -3.36 | -0.57 | -0.49 | -0.41 | -2.78 | - | - | - | - | - |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.41 | -5.03 | -2.11 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | ||
|
Anika Therapeutics
ANIK
|
-5.64 | $ 14.21 | -0.42 % | $ 208 M | ||
|
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B | ||
|
Aileron Therapeutics
ALRN
|
-3.51 | - | 10.36 % | $ 9.8 M | ||
|
Altimmune
ALT
|
-1 | $ 3.35 | -2.62 % | $ 295 M | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
-8.28 | $ 216.26 | -0.83 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 19.12 | -0.57 % | $ 894 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
-1.45 | $ 0.62 | 2.14 % | $ 7.1 M | ||
|
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | ||
|
CRISPR Therapeutics AG
CRSP
|
-6.47 | $ 46.45 | -0.91 % | $ 4.18 B | ||
|
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | ||
|
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-0.86 | $ 1.4 | -0.36 % | $ 357 M | ||
|
Exelixis
EXEL
|
2.88 | $ 41.13 | -0.69 % | $ 11.2 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
-1.89 | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
-2.16 | $ 2.63 | - | $ 16.5 M | ||
|
Fulcrum Therapeutics
FULC
|
-1.18 | $ 6.64 | -3.63 % | $ 421 K | ||
|
Atreca
BCEL
|
-2.52 | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | ||
|
Genmab A/S
GMAB
|
34.4 | $ 25.59 | -0.35 % | $ 16.5 B | ||
|
Grifols, S.A.
GRFS
|
0.28 | $ 7.64 | -0.72 % | $ 6.83 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B | ||
|
Halozyme Therapeutics
HALO
|
2.64 | $ 61.68 | -1.88 % | $ 7.39 B | ||
|
Harmony Biosciences Holdings
HRMY
|
2.76 | $ 26.99 | -2.21 % | $ 1.55 B | ||
|
Bellerophon Therapeutics
BLPH
|
-2.08 | - | -74.18 % | $ 955 K | ||
|
ImmuCell Corporation
ICCC
|
-0.26 | $ 6.43 | 0.31 % | $ 52.5 M | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | ||
|
Immatics N.V.
IMTX
|
-4.77 | $ 9.32 | -2.0 % | $ 586 M | ||
|
Ionis Pharmaceuticals
IONS
|
-1.41 | $ 69.48 | -1.85 % | $ 11.1 B | ||
|
Innate Pharma S.A.
IPHA
|
-0.66 | $ 1.33 | -2.92 % | $ 235 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-0.17 | $ 4.29 | -2.94 % | $ 822 M | ||
|
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M |